AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints

10:07 AM EDT, 09/03/2026 (MT Newswires) -- AbbVie's (ABBV) phase 3 study of etentamig in patients with triple-class exposed relapsed/refractory multiple myeloma met its dual primary endpoints of objective response rate and progression-free survival, the company said Thursday. Trial results, which covered 393 patients, demonstrated significantly higher objective response rate and improved progression-free survival with etentamig compared with standard available therapies, AbbVie said. AbbVie plans to discuss the phase 3 study's results with regulatory authorities globally to determine the next development steps for etentamig, according to the statement. Price: 259.59, Change: -2.12, Percent Change: -0.81